Adam's Take

Adam's Take By Adam Feuerstein

A company developing a human blood substitute attempts a comeback, but IPO plans look dicey

Adam's Take By Adam Feuerstein

What Regeneron’s purchase of Checkmate Pharma says about the state of biotech

Adam's Take By Adam Feuerstein

Cel-Sci’s CEO used private call to tip off select investors about cancer drug update

Adam's Take By Adam Feuerstein

Troubles mount for Cassava Sciences, as patient enrollment lags for Alzheimer’s drug studies

Adam's Take By Adam Feuerstein

Be careful who you sue: CytoDyn knowingly submitted an incomplete drug application to FDA, new documents show

Adam's Take By Adam Feuerstein

An FDA rejection derails Omeros, exposing the empty promises of its CEO

dementia alzheimer's disease progression

Adam's Take By Adam Feuerstein

Alzheimer’s scientists critique Cassava Sciences’ study results — overblown, inappropriate, uninterpretable

Adam's Take By Adam Feuerstein

The failure of a cancer drug study leaves Cel-Sci on the brink of collapse

Adam's Take By Adam Feuerstein

Cel-Sci CEO spoke privately with investors last week, raising doubts about long-delayed cancer drug

Adam's Take By Adam Feuerstein

Fibrogen’s data manipulation scandal came with questions. There need to be answers

Adam's Take By Adam Feuerstein

A ‘conditional’ EUA for a CytoDyn Covid treatment? FDA says no such thing exists

Adam's Take By Adam Feuerstein

Who will Vertex buy? How much will it spend? Deal questions dominate its earnings call

Adam's Take By Adam Feuerstein

Why did this small biotech blow up? Because spinning bad drug data never works

Adam's Take By Adam Feuerstein

Vertex, Amgen could be seeking new deals to fuel growth following pipeline stumbles

Adam's Take By Adam Feuerstein

Failure has paid handsomely for Cassava Sciences’ CEO. His latest cash grab is a risky Alzheimer’s drug

Adam's Take By Adam Feuerstein

Do surprise drug rejections signal a more conservative FDA? Don’t bet on it

Adam's Take By Adam Feuerstein

Applied Therapeutics’ muted response to a clinical hold speaks volumes

Adam's Take By Adam Feuerstein

CytoDyn is in financial and clinical distress, newly filed annual report shows

Adam's Take By Adam Feuerstein

CytoDyn CEO claims Covid-19 drug success while describing data suggesting study failure

Adam's Take By Adam Feuerstein

CytoDyn’s Covid-19 drug troubles escalate: Efficacy data are missing from study

Adam's Take By Adam Feuerstein

Moderna’s skyrocketing market value is an indictment of the U.S. Covid-19 response

Adam's Take By Adam Feuerstein

Applied Therapeutics amends investor deck, bolstering accusations made by anonymous critic

Adam's Take By Adam Feuerstein

FDA refuses application for HIV drug from CytoDyn, raising more questions about its credibility

Adam's Take By Adam Feuerstein

A moment of truth arrives for CytoDyn’s Covid-19 drug. Don’t let spin obscure it

Adam's Take By Adam Feuerstein

Most Read

Aurinia Pharma’s takeout hopes dim with new legal challenge to key drug patent

An FDA ruling on Cassava’s Alzheimer’s drug leaves bulls and bears waiting for more

Northwest Bio marks ignominious anniversary of brain tumor study delay with silence

In new remarks, Cassava Sciences’ CEO shifts defense of embattled treatment for Alzheimer’s

FDA issues major rebuke to CytoDyn over claims on Covid-19 drug

The long wait for Cel-Sci to finally admit its cancer drug doesn’t work

CytoDyn’s wild weekend of data-mining study results ends in failure for its Covid treatment

Kulkarni victorious in best biopharma CEO vote; Leschly tops worst list

All Coverage

A company developing a human blood substitute attempts a comeback, but IPO plans look dicey

What Regeneron’s purchase of Checkmate Pharma says about the state of biotech

Cel-Sci’s CEO used private call to tip off select investors about cancer drug update

Troubles mount for Cassava Sciences, as patient enrollment lags for Alzheimer’s drug studies

Be careful who you sue: CytoDyn knowingly submitted an incomplete drug application to FDA, new documents show

An FDA rejection derails Omeros, exposing the empty promises of its CEO

Alzheimer’s scientists critique Cassava Sciences’ study results — overblown, inappropriate, uninterpretable

The failure of a cancer drug study leaves Cel-Sci on the brink of collapse

Cel-Sci CEO spoke privately with investors last week, raising doubts about long-delayed cancer drug

Fibrogen’s data manipulation scandal came with questions. There need to be answers

A ‘conditional’ EUA for a CytoDyn Covid treatment? FDA says no such thing exists

Who will Vertex buy? How much will it spend? Deal questions dominate its earnings call

Why did this small biotech blow up? Because spinning bad drug data never works

Vertex, Amgen could be seeking new deals to fuel growth following pipeline stumbles

Failure has paid handsomely for Cassava Sciences’ CEO. His latest cash grab is a risky Alzheimer’s drug

Do surprise drug rejections signal a more conservative FDA? Don’t bet on it

Applied Therapeutics’ muted response to a clinical hold speaks volumes

CytoDyn is in financial and clinical distress, newly filed annual report shows

CytoDyn CEO claims Covid-19 drug success while describing data suggesting study failure

CytoDyn’s Covid-19 drug troubles escalate: Efficacy data are missing from study

Moderna’s skyrocketing market value is an indictment of the U.S. Covid-19 response

Applied Therapeutics amends investor deck, bolstering accusations made by anonymous critic

FDA refuses application for HIV drug from CytoDyn, raising more questions about its credibility

A moment of truth arrives for CytoDyn’s Covid-19 drug. Don’t let spin obscure it

ASCO 2020 takeaways: AstraZeneca does a star turn, KRAS fizzles, and cell therapy shows progress

Subscribe to STAT for $15 per month lorem ipsum

Adam’s Take

Most Read

All Coverage

Subscribe to STAT for $15 per month lorem ipsum